Provides brief background on current Medicare pharmaceutical pricing and policy implications; discusses types of pricing policies used by VA and Medicaid to stem a rise in drug expenditures; and examines implications of negotiating drug prices and options that may lower costs for the Medicare Part D Program and its beneficiaries.
ProQuest U.S. Congressional Research Digital Collection
Note
Record is based on bibliographic data in ProQuest U.S. Congressional Research Digital Collection (last viewed Dec. 2010). Reuse except for individual research requires license from ProQuest, LLC. CRS Report. AVAILABLE ONLINE TO AUTHORIZED PSU USERS.